2. Shellenberg et al. An update on the clinical pharmacology of Methylphenidate: therapeutic efficacy, abuse potential and future considerations. Expert Rev Clin Pharmacol. 2020;13:825–33.
3. Faraone S V. The pharmacology of amphetamine and Methylphenidate: Relevance to the neurobiology of attention-deficit/hyperactivity disorder and other psychiatric comorbidities. Neurosci Biobehav Rev. 2018;87:255–70.
4. FDA. Methylphenidate hydrochloride extended-release capsules. 2024. https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/021284s020lbl.pdf
9. TGA. AUSTRALIAN PRODUCT INFORMATION Methylphenidate. 2024. https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent=&id=CP-2010-PI-03175-3&d=20240704172310101&d=20240722172310101
10. Stevens et al. PharmGKB summary: Methylphenidate pathway, pharmacokinetics/pharmacodynamics. 2019. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6581573/pdf/nihms-1525130.pdf